ConductScience.org, home

Paper · 34412058

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131506303Nusinersen for Type 1 Spinal Muscular Atrophy: A Father's Perspective.Pediatrics2019https://conductscience.org/library/papers/31506303PubMed
217537961Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation.J Neurosci2007https://conductscience.org/library/papers/17537961PubMed
38390996Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression.J Biol Chem1993https://conductscience.org/library/papers/8390996PubMed
433531663Sodium channelopathies in neurodevelopmental disorders.Nat Rev Neurosci2021https://conductscience.org/library/papers/33531663PubMed
524784568Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates.J Pharmacol Exp Ther2014https://conductscience.org/library/papers/24784568PubMed
625568300The phenotypic spectrum of SCN8A encephalopathy.Neurology2015https://conductscience.org/library/papers/25568300PubMed
733307321Children and young adults with spinal muscular atrophy treated with nusinersen.Eur J Paediatr Neurol2021https://conductscience.org/library/papers/33307321PubMed
828192393Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy.Nat Neurosci2017https://conductscience.org/library/papers/28192393PubMed
920624852Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.Genes Dev2010https://conductscience.org/library/papers/20624852PubMed
1031943325Scn8a Antisense Oligonucleotide Is Protective in Mouse Models of SCN8A Encephalopathy and Dravet Syndrome.Ann Neurol2020https://conductscience.org/library/papers/31943325PubMed
119259265The survival motor neuron protein in spinal muscular atrophy.Hum Mol Genet1997https://conductscience.org/library/papers/9259265PubMed
129077498A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients.J Neurol Sci1997https://conductscience.org/library/papers/9077498PubMed
1331036929Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.Nat Biotechnol2019https://conductscience.org/library/papers/31036929PubMed
1428244990The chemical evolution of oligonucleotide therapies of clinical utility.Nat Biotechnol2017https://conductscience.org/library/papers/28244990PubMed
159880552Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression.J Biol Chem1999https://conductscience.org/library/papers/9880552PubMed
1621971427Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.Mol Ther2011https://conductscience.org/library/papers/21971427PubMed
1727939059Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.Lancet2016https://conductscience.org/library/papers/27939059PubMed
187813012Identification and characterization of a spinal muscular atrophy-determining gene.Cell1995https://conductscience.org/library/papers/7813012PubMed
1929091557Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.N Engl J Med2017https://conductscience.org/library/papers/29091557PubMed
2021482919Spinal muscular atrophy: a timely review.Arch Neurol2011https://conductscience.org/library/papers/21482919PubMed

papers-2026-11-12-0.1.0

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/34412058/references